129 related articles for article (PubMed ID: 30231337)
1. Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance.
Hall MJ; Morris AM; Sun W
Am Soc Clin Oncol Educ Book; 2018 May; 38():220-230. PubMed ID: 30231337
[TBL] [Abstract][Full Text] [Related]
2. Optimizing adjuvant therapy and survivorship care of stage III colon cancer.
Loree JM; Cheung WY
Future Oncol; 2016 Sep; 12(17):2021-35. PubMed ID: 27301775
[TBL] [Abstract][Full Text] [Related]
3. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
[TBL] [Abstract][Full Text] [Related]
4. Colon cancer.
Labianca R; Beretta GD; Kildani B; Milesi L; Merlin F; Mosconi S; Pessi MA; Prochilo T; Quadri A; Gatta G; de Braud F; Wils J
Crit Rev Oncol Hematol; 2010 May; 74(2):106-33. PubMed ID: 20138539
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Tang M; Price TJ; Shapiro J; Gibbs P; Haller DG; Arnold D; Peeters M; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M
Expert Rev Anticancer Ther; 2018 Apr; 18(4):339-349. PubMed ID: 29478352
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Emerging Risk Factors in Colon Cancer-End of the Line for Clinomics?
Osterman E; Glimelius B
Ann Surg Oncol; 2020 Apr; 27(4):1046-1047. PubMed ID: 31884560
[No Abstract] [Full Text] [Related]
8. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for colon cancer.
Saltz LB
Surg Oncol Clin N Am; 2010 Oct; 19(4):819-27. PubMed ID: 20883956
[TBL] [Abstract][Full Text] [Related]
11. To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology.
Giannakis M; Ng K
J Oncol Pract; 2017 Apr; 13(4):242-244. PubMed ID: 28399380
[No Abstract] [Full Text] [Related]
12. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
Van Cutsem EJ; Oliveira J;
Ann Oncol; 2008 May; 19 Suppl 2():ii29-30. PubMed ID: 18456758
[No Abstract] [Full Text] [Related]
13. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer.
Dey A; Mitra A; Pathak S; Prasad S; Zhang AS; Zhang H; Sun XF; Banerjee A
Technol Cancer Res Treat; 2023; 22():15330338231178403. PubMed ID: 37248615
[TBL] [Abstract][Full Text] [Related]
14. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant therapy for colon cancer].
Fey MF
Schweiz Med Wochenschr; 2000 Nov; 130(46):1760-5. PubMed ID: 11127955
[TBL] [Abstract][Full Text] [Related]
16. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009.
Du XL; Zhang Y; Parikh RC; Lairson DR; Cai Y
J Am Geriatr Soc; 2015 Aug; 63(8):1570-82. PubMed ID: 26200214
[TBL] [Abstract][Full Text] [Related]
18. [The application of molecular technics in the management of colorectal cancer].
Laurent-Puig P; Cugnenc PH
J Chir (Paris); 1997 Dec; 134(7-8):279-82. PubMed ID: 9772989
[TBL] [Abstract][Full Text] [Related]
19. New adjuvant therapy for colon cancer: justified hope or commercial hype.
Galanis E; Alberts SR; O'Connell MJ
Surg Oncol Clin N Am; 2000 Oct; 9(4):813-23; discussion 825-6. PubMed ID: 11008249
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
